Duodenum cancer

Summary

Duodenum cancer (MONDO:0000920) is a cancer and 5 clinical trials. Top therapeutic interventions include irinotecan. A subtype of small intestine cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	duodenum cancer
Mondo ID	MONDO:0000920
MeSH	D004379
DOID	DOID:10021
ICD-10-CM	C17.0
ICD-11	1527322574
NCIT	C9328
SNOMED CT	363403002
UMLS	C0153426
MedGen	56301
GARD	0022846
Anatomy (UBERON)	UBERON:0002114
Is cancer (heuristic)	yes

Also known as: cancer of duodenum · duodenum cancer · malignant duodenal neoplasm · malignant duodenal tumor · malignant duodenal tumour · malignant duodenum neoplasm · malignant neoplasm of duodenum · malignant neoplasm of the duodenum · malignant tumor of duodenum · malignant tumor of the duodenum · malignant tumour of duodenum · malignant tumour of the duodenum

Disease family

This is a subtype of small intestine cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal neoplasm › small intestine neoplasm › small intestine cancer › duodenum cancer

Related subtypes (5): ileum cancer, small intestine lymphoma, small intestinal sarcoma, small intestine carcinoma, jejunal cancer

Subtypes (2): ampulla of vater cancer, carcinoma of duodenum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00183846	PHASE1	COMPLETED	Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
NCT06076252	Not specified	ENROLLING_BY_INVITATION	Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
NCT07199127	Not specified	RECRUITING	Duodenal Polyposis Classification in FAP
NCT03150615	Not specified	COMPLETED	Enteral Nutrition After Pancreaticoduodenectomy
NCT04843397	Not specified	UNKNOWN	Diagnostic Performance Indicators in Upper GI Endoscopy:PROSPERO Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IRINOTECAN	4	1